Revive Therapeutics Announces Approval of CSE Listing and Delisting from TSX-V
July 19 2019 - 10:03AM
Revive Therapeutics Ltd. ("
Revive" or the
"
Company") (TSX VENTURE: RVV) (OTCQB: RVVTF), a
specialty cannabis company focused on the research, development,
and commercialization of novel cannabinoid-based products, is
pleased to announce that it has received final approval to list its
common shares on the Canadian Securities Exchange (the
"
CSE"), and intends to voluntarily delist its
common shares from the TSX Venture Exchange (the
"
TSX-V"). The common shares will commence trading
on the CSE at the market opening on July 23, 2019.
The de-listing of the common shares from the TSX-V is expected to
become effective after the market close on July 22, 2019.
“We believe that the listing on the CSE will
allow us to execute on our strategic plans in pursuing
opportunities in the cannabis and hemp-derived CBD markets in the
U.S. and Europe, while providing shareholders continued liquidity
on a recognized Canadian stock exchange,” said Craig Leon, Chief
Executive Officer of Revive.
About Revive Therapeutics Ltd.
Revive Therapeutics Ltd. (TSX VENTURE: RVV)
(OTCQB: RVVTF) (FSE: 31R) is a specialty cannabis company focused
on the research, development and commercialization of novel
cannabinoid-based products. The Company’s novel cannabinoid
delivery technology is being advanced to fill the medical needs for
diseases and disorders such as pain, inflammation, and wound care.
Revive’s cannabinoid pharmaceutical portfolio focuses on rare
inflammatory and liver diseases. For more information, visit
www.ReviveThera.com.
For more information please contact:
Craig Leon – Chief Executive OfficerRevive
Therapeutics Ltd.Tel: (416) 272-5525Email:
craig@revivethera.com
Website:
www.revivethera.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS
Neither the TSX-V nor its Regulation Services
Provider (as that term is defined in the policies of the TSX-V)
accepts responsibility for the adequacy or accuracy of this
release.
This news release includes certain information
and statements about management's view of future events,
expectations, plans and prospects that constitute "forward looking
statements", which are not comprised of historical facts.
Forward-looking statements may be identified by such terms as
"believes", "anticipates", "intends", "expects", "estimates",
"may", "could", "would", "will", or "plan", and similar
expressions. Forward-looking information is based on certain key
expectations and assumptions made by the management of the Company,
including the statements regarding: (i) the expected delisting of
the Company’s common shares from the TSX-V; and (ii) the expected
listing of the Company’s common shares on the CSE. These statements
involve known and unknown risks, uncertainties, and other factors
that may cause actual results or events, performance, or
achievements of Revive to differ materially from those anticipated
or implied in such forward-looking statements. Although the Company
believes that the expectations and assumptions on which such
forward-looking information is based are reasonable, undue reliance
should not be placed on the forward-looking information because the
Company can give no assurance that they will prove to be correct.
Forward-looking statements contained in this press release are made
as of the date of this press release. Given these risks and
uncertainties, readers are cautioned not to place undue reliance on
such forward-looking statements and information, which are
qualified in their entirety by this cautionary statement. Except as
required by law, Revive disclaims any intention and assumes no
obligation to update or revise any forward-looking statements to
reflect actual results, whether as a result of new information,
future events, changes in assumptions, changes in factors affecting
such forward-looking statements or otherwise.
Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Jul 2023 to Jul 2024